Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

TYPE OF SARCOMA: Uterine Leiomyosarcoma
DRUG: Gemcitabine and Docetaxel
ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Martee L. Hensley, MD
Memorial Sloan Kettering Cancer Center

CLINICALTRIALS.GOV IDENTIFIER: NCT00282087

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

To learn more about this study or to contact the study research staff: